Phospho-MARCKS (Ser170) Antibody

What is MARCKS protein and what is the significance of its phosphorylation at Ser170?

MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) is a major PKC substrate expressed in many cell types. It plays crucial roles in multiple cellular processes including cell motility, cell adhesion, phagocytosis, membrane traffic, and mitogenesis . The protein contains several phosphorylation sites, with Ser170 being one of the key regulatory sites.

Phosphorylation at Ser170 is particularly significant because it affects MARCKS' binding capacity to calcium/calmodulin and its filamentous (F)-actin cross-linking activities . When MARCKS becomes phosphorylated at this site in response to growth factors or oxidative stress, it translocates from the plasma membrane to the cytoplasm, fundamentally altering its functionality .

How does the Phospho-MARCKS (Ser170) antibody specifically detect the phosphorylated form?

The Phospho-MARCKS (Ser170) antibody specifically recognizes the peptide sequence around the phosphorylation site of Serine 170 (G-F-S(p)-F-K) derived from human MARCKS . The antibody is designed to detect endogenous levels of MARCKS protein only when phosphorylated at Ser170, not recognizing the non-phosphorylated form .

High-quality antibodies undergo purification by affinity chromatography using epitope-specific phosphopeptides, and importantly, non-phospho specific antibodies are removed by chromatography using non-phosphopeptides . This rigorous purification process ensures the antibody's specificity for the phosphorylated form of MARCKS at Ser170.

What are the validated applications for Phospho-MARCKS (Ser170) antibody?

Based on the technical specifications, Phospho-MARCKS (Ser170) antibodies have been validated for the following applications:

The antibody specifically detects endogenous levels of MARCKS when phosphorylated at Ser170 in human samples . Some antibodies may detect MARCKS in other species if the antigenic sequence is conserved, but researchers should verify cross-reactivity if working with non-human samples.

What is the difference between Phospho-MARCKS (Ser170) and Phospho-MARCKS (Ser167/170) antibodies?

The key difference lies in their epitope specificity:

• Phospho-MARCKS (Ser170) antibody: Specifically detects MARCKS phosphorylated at Serine 170 only .

• Phospho-MARCKS (Ser167/170) antibody: Recognizes MARCKS when phosphorylated at both Ser167 and Ser170, and may also detect MARCKS mono-phosphorylated at Ser167 .

This distinction is critical for experimental design when researchers need to distinguish between different phosphorylation patterns. The Phospho-MARCKS (Ser167/170) antibody offers broader detection of phosphorylation events in the MARCKS phosphorylation site domain (PSD), while the Ser170-specific antibody provides more precise information about phosphorylation at that particular residue.

What are the optimal storage and handling conditions for Phospho-MARCKS (Ser170) antibody?

For maximum stability and performance, researchers should adhere to the following guidelines:

Proper storage and handling are essential to maintain antibody activity and specificity for accurate experimental results.

How can researchers use Phospho-MARCKS (Ser170) antibody to study cancer progression mechanisms?

Phospho-MARCKS antibodies serve as valuable tools for investigating cancer progression through several key approaches:

What are the technical considerations for optimizing Western blot analysis using Phospho-MARCKS (Ser170) antibody?

For optimal Western blot results with Phospho-MARCKS (Ser170) antibody, researchers should consider:

• Sample preparation:

  • Preserve phosphorylation status by including phosphatase inhibitors in lysis buffers

  • Use fresh samples or properly snap-frozen tissues to prevent phospho-epitope degradation

  • Standardize protein extraction methods for consistent results

• Controls:

  • Positive control: MCF-7 cells are recommended

  • Negative control: Consider using dephosphorylated samples or MARCKS knockout/knockdown cells

  • Treatment control: Compare samples with and without PKC activators/inhibitors

• Detection parameters:

  • Molecular weight: Expect bands at approximately 80 kDa for human MARCKS and 75 kDa for rodent MARCKS

  • Recommended antibody dilution: 1:1000 for Western blotting

  • Secondary antibody: Anti-rabbit IgG is appropriate as the primary antibodies are typically rabbit-derived

• Troubleshooting non-specific binding:

  • Optimize blocking conditions (5% BSA often works better than milk for phospho-epitopes)

  • Include appropriate washing steps to reduce background

  • Consider using lower antibody concentrations if background is high

What experimental approaches can be used to study the functional consequences of MARCKS phosphorylation at Ser170?

Several experimental approaches can be employed to investigate functional consequences:

• Genetic manipulation:

  • shRNA silencing of MARCKS

  • Ectopic expression of wild-type MARCKS

  • Site-directed mutagenesis to create phospho-mimetic (S170D/E) or phospho-deficient (S170A) MARCKS mutants

  • As demonstrated in research, S159/163A MARCKS mutants have been used to study phosphorylation effects on cancer growth

• Pharmacological interventions:

  • Treating cells with the MPS peptide that targets the MARCKS PSD motif

  • Using PKC activators (e.g., PMA) or inhibitors to modulate MARCKS phosphorylation

  • Combining with drugs like erlotinib to study effects on drug sensitivity

• Functional assays:

  • Cell motility and invasion assays

  • Proliferation and apoptosis measurements

  • Drug resistance assays

  • Membrane-cytoplasm fractionation to track MARCKS translocation

• Molecular interaction studies:

  • Co-immunoprecipitation to study interaction with PI3K and other binding partners

  • Phospholipid binding assays to measure effects on membrane interactions

What are the optimal protocols for immunohistochemistry using Phospho-MARCKS (Ser170) antibody on FFPE tissue sections?

For successful immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) tissue sections:

• Tissue preparation:

  • Cut sections at 4-6 μm thickness

  • Use positively charged slides to improve tissue adherence

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) is typically recommended

  • Citrate buffer (pH 6.0) or EDTA buffer (pH 8.0) can be used

  • Optimize retrieval time and temperature based on specific tissue type

• Blocking and antibody incubation:

  • Block endogenous peroxidase activity

  • Use protein blocking solution to reduce non-specific binding

  • Follow manufacturer's recommended dilution (typically starting with 1:100 for IHC)

  • Incubate at 4°C overnight for optimal signal-to-noise ratio

• Controls and validation:

  • Human lung carcinoma is recommended as a positive control

  • Include no-primary-antibody controls

  • Consider phosphatase-treated sections as negative controls

• Signal development and interpretation:

  • Use appropriate detection systems (HRP/DAB or fluorescent)

  • Counter-stain with hematoxylin for morphological context

  • Evaluate staining in known MARCKS-expressing compartments (membrane vs. cytoplasm)

How should researchers interpret immunohistochemistry results for Phospho-MARCKS (Ser170) in cancer tissues?

Proper interpretation requires attention to several key aspects:

How can Phospho-MARCKS (Ser170) antibody be used to evaluate potential cancer therapeutics?

Phospho-MARCKS (Ser170) antibody serves as a valuable tool in therapeutic development through several approaches:

• Target validation:

  • Monitor changes in MARCKS phosphorylation in response to novel therapeutic agents

  • Validate the mechanism of action for compounds designed to modulate PKC signaling

  • Assess on-target effects of MARCKS-directed therapeutics like the MPS peptide

• Pharmacodynamic markers:

  • Use phospho-MARCKS levels as pharmacodynamic biomarkers to determine optimal dosing

  • Monitor treatment response in preclinical models and potentially in clinical samples

  • Establish the timeline of phosphorylation changes during treatment

• Resistance mechanisms:

  • Investigate the role of MARCKS phosphorylation in resistance to targeted therapies

  • Research has shown that elevated phospho-MARCKS promoted cancer growth and erlotinib resistance

  • Study combination approaches that target MARCKS phosphorylation to overcome resistance

• Patient selection strategies:

  • Develop companion diagnostic approaches based on phospho-MARCKS status

  • Identify patient populations most likely to benefit from therapies targeting this pathway

  • Correlate baseline phospho-MARCKS levels with treatment outcomes

What is the relationship between MARCKS phosphorylation and the PI3K/AKT pathway in cancer?

Research has revealed several important connections between MARCKS phosphorylation and PI3K/AKT signaling:

What are common troubleshooting issues when working with Phospho-MARCKS (Ser170) antibody?

Researchers may encounter several challenges when working with phospho-specific antibodies:

• Loss of phospho-epitope:

  • Ensure all buffers contain phosphatase inhibitors

  • Minimize sample handling time

  • Avoid repeated freeze-thaw cycles of samples

  • Process tissues rapidly after collection

• High background:

  • Optimize blocking conditions (BSA often works better than milk for phospho-epitopes)

  • Increase washing duration and frequency

  • Reduce primary antibody concentration

  • Test different detection systems

• Weak or absent signal:

  • Verify phosphorylation status (consider using PKC activators as positive controls)

  • Optimize antigen retrieval for IHC applications

  • Test different lysis conditions for Western blotting

  • Ensure antibody storage conditions have been maintained properly

• Non-specific bands in Western blot:

  • Increase blocking time and stringency

  • Optimize antibody dilution

  • Consider longer and more stringent washing steps

  • Use gradient gels to better resolve proteins of similar molecular weight

How can researchers quantify phospho-MARCKS levels accurately for comparative studies?

Accurate quantification requires rigorous methodology:

• Western blot quantification:

  • Use appropriate loading controls (total MARCKS, housekeeping proteins)

  • Calculate phospho-MARCKS/total MARCKS ratio to normalize for expression differences

  • Employ standard curves with recombinant phospho-proteins when absolute quantification is needed

  • Use digital imaging systems with validated linear dynamic range

• Image analysis for IHC:

  • Employ digital pathology systems for standardized scoring

  • Use image analysis software to quantify staining intensity and distribution

  • Establish consistent thresholds for positive staining

  • Consider automated systems to reduce observer bias

• Flow cytometry approaches:

  • Use standardized beads to calibrate fluorescence intensity

  • Compare median fluorescence intensity (MFI) rather than percentage positive

  • Include appropriate isotype controls

  • Consider dual staining with total MARCKS to normalize for expression levels

• Experimental design considerations:

  • Include biological and technical replicates

  • Process all samples for comparison simultaneously

  • Use the same lot of antibody for comparative studies

  • Include appropriate statistical analyses for significance testing